Mesoblast (ASX:MSB) said gross sales for Ryoncil, its mesenchymal stromal cell product, during the March quarter were $35.3 million, according to a Thursday Australian bourse filing.
Net revenue was $30.3 million, bringing the revenue generated during the first year of the product's launch to nearly $100 million, per the filing.
Receipts from customers were $34.6 million in the March quarter, compared with $1.5 million in the year-ago period.
Mesoblast's shares fell nearly 5% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments